Recent news on Perindopril Erbumine

CV Therapeutics Ending Co-Promotion of ACEON(R) (perindopril ...  Oct 11, 2006
There are no financial commitments for either company related to the termination of the co-promotion agreement. CV Therapeutics ... -Earthtimes.org CV Therapeutics Ending Co-Promotion of ACEON(R) (perindopril ...  Oct 11, 2006
Pharmaceuticals, Inc. a notice of termination under the companies' co-promotion agreement for ACEON® (perindopril erbumine) Tablets. Over ... -Yahoo! News (press release) International Approvals: Coversyl, Exjade, and Loramyc  Oct 27, 2006
October 27, 2006 — Health Canada has approved a new indication for perindopril erbumine, allowing its use to reduce the risk for cardiovascular adverse ... -Medscape (subscription) CV Therapeutics Reports 2006 Third Quarter Financial Results  Oct 31, 2006
There was no co-promotion revenue recognized for the quarter ended September 30, 2006 related to sales of ACEON(R) (perindopril erbumine) Tablets since ACEON(R ... -MSN Money CV Therapeutics To End Co-promotion Deal For ACEON Tablets With ...  Oct 11, 2006
Solvay Pharmaceuticals, Inc. under the companies' co-promotion agreement for ACEON or perindopril erbumine Tablets. CV Therapeutics ... -Trading Markets, (PRN) - Micrel Introduces New Ultra-Low Dropout Regulator ...  Oct 11, 2006
...[+]. (PRN) - CV Therapeutics Ending Co-Promotion of ACEON(R) (perindopril erbumine) Tablets ... [+. PRN) - Demand for GridApp Systems 'Ready. Set. ... -Bolsamania.com, CV Therapeutics Announces Seven Abstracts Accepted for ...  Aug 24, 2006
CV Therapeutics' approved products include Ranexa(R) (ranolazine extended- release tablets) and ACEON(R) (perindopril erbumine) Tablets. ... -PR Newswire

Abbott to shame 'below-par' hospitals  -  Nov 16, 2006
NEWS.com.au,Pharmacists expect more than 400 medicine brands - such as the antibiotic amoxycillin and blood pressure drug perindopril erbumine - to fall in price as a ...

CV Therapeutics Announces Seven Abstracts Accepted for ...  Aug 24, 2006
CV Therapeutics' approved products include Ranexa® (ranolazine extended- release tablets) and ACEON® (perindopril erbumine) Tablets. ... -Yahoo! News

CV Therapeutics Announces Seven Abstracts Accepted for ...  Aug 24, 2006
CV Therapeutics' approved products include Ranexa(R) (ranolazine extended- release tablets) and ACEON(R) (perindopril erbumine) Tablets. ... -Genetic Engineering News

CV Therapeutics Brings In $85.5M Via Public Offering  Aug 16, 2006
The company's second marketed product, ACEON (perindopril erbumine tablets), is approved to reduce the risk of cardiovascular mortality or nonfatal myocardial ... -BioWorld Online

CV Therapeutics Reports 2006 Second Quarter Financial Results  Aug 3, 2006
...contract expenses for the regadenoson development program and lower marketing expenses related to the co-promotion of ACEON® (perindopril erbumine) Tablets. ... -Yahoo! News

CV Therapeutics to Announce 2006 Second Quarter Financial Results ...  Jul 20, 2006
CV Therapeutics' approved products include Ranexa(R) (ranolazine extended- release tablets) and ACEON(R) (perindopril erbumine) Tablets. ... -PR Newswire

CV Therapeutics Announces MERLIN TIMI-36 Study To Continue As ...  Jul 9, 2006
CV Therapeutics' approved products include Ranexa(R) (ranolazine extended-release tablets) and ACEON(R) (perindopril erbumine) Tablets. ... -Medical News Today

CV Therapeutics Announces MERLIN TIMI-36 Study to Continue as ...  Jul 7, 2006
CV Therapeutics' approved products include Ranexa® (ranolazine extended-release tablets) and ACEON® (perindopril erbumine) Tablets. ... -Yahoo! News



Angina Patients Cost Managed Care Over Twice as Much as Coronary ...  May 9, 2006
CV Therapeutics' approved products include Ranexa(TM) (ranolazine extended-release tablets) and ACEON® (perindopril erbumine) Tablets. ... - Yahoo! News

CV Therapeutics Reports 2006 First Quarter Financial Results  Apr 25, 2006
...quarters of 2005, other expenses incurred to launch Ranexa(TM) (ranolazine extended-release tablets) and co-promote ACEON(R) (perindopril erbumine) Tablets and ... - PR Newswire

CV Therapeutics Reports Option Grants Under Nasdaq Marketplace ...  Apr 18, 2006
...in connection with its commercialization efforts to promote Ranexa(TM) (ranolazine extended- release tablets) and ACEON(R) (perindopril erbumine) Tablets in ... - PharmaLive.com





CV Therapeutics Launches Ranexa  Mar 24, 2006
CV Therapeutics' approved products include Ranexa(TM) (ranolazine extended-release tablets) and ACEON(R) (perindopril erbumine) Tablets. ... - PR Newswire



CV Therapeutics Reports Option Grants Under Nasdaq Marketplace ...  Feb 28, 2006
...in connection with its commercialization efforts to promote Ranexa(TM) (ranolazine extended-release tablets) and ACEON(R) (perindopril erbumine) Tablets in the ... - PR Newswire,

CV Therapeutics Announces MERLIN TIMI-36 Study to Continue as ...  09 Feb 2006
CV Therapeutics' approved products include Ranexa(TM) (ranolazine extended-release tablets) and ACEON(R) (perindopril erbumine) Tablets. ... - PR Newswire

FDA Approves Ranexa  Jan 27, 2006
CV Therapeutics' approved products include Ranexa(TM) (ranolazine extended-release tablets) and ACEON® (perindopril erbumine) Tablets. ... - Yahoo! News

CV Therapeutics Gets FDA OK To Sell Ranexa In Angina  Jan 30, 2006
...sales representatives already have been getting to know cardiovascular doctors through sales of the ACE inhibitor Aceon (perindopril erbumine) for the past two ... - BioWorld Online (subscription)

CV Therapeutics Appoints Joseph M. Davie, MD, Ph.D. to Board of ...  Jan 13, 2006
CV Therapeutics currently has three programs in commercial or late-stage development: ACEON® (perindopril erbumine) Tablets, Ranexa(TM) (ranolazine) and ... - Yahoo! News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional